Cancer Guidelines Database

Access quality cancer guidelines from a single Canadian source

We've listed 49 guidelines under your selection of "Type of cancer". The most recent guidelines are first.

Guidelines of Care for the Management of Primary Cutaneous Melanoma

Year: 2019
AGREE II score: Available
Developer organization: American Academy of Dermatology
This is a clinical practice guideline for patients with primary cutaneous melanoma. The guideline provides treatment recommendations for this patient population, including recommendations for surgical margins. Specific topics discussed include biopsy techniques for lesions that are clinically suggestive of melanoma, histopathologic interpretation of cutaneous melanoma, the use of laboratory, molecular, and imaging tests during initial work-up or follow-up, as well as the concept of staged excision.

Merkel Cell Carcinoma

Year: 2019
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for adult patients with Merkel cell carcinoma. The guideline examines the staging and work-up, treatment, follow-up, and management of recurrence in these patients. Treatment options discussed include surgery, radiation, chemotherapy, and immunotherapy. Clinical scenarios including clinical node-negative, clinical node-positive, and metastatic are considered, as is sentinel lymph node biopsy protocol.

Non-Melanoma

Year: 2019
AGREE II score: Unavailable
Developer organization: BC Cancer Agency
This is a clinical practice guideline for patients with non-melanoma skin cancer. The guideline discusses prevention, staging, treatment, and follow-up for these patients. Specific diseases discussed include basal cell carcinoma, squamous cell carcinoma, keratoacanthomas, Merkel cell tumours, Kaposi's sarcoma, extramammary Paget's disease (EMPD), and other non-melanoma skin cancers. Please note that the sub-sections within this set were published and revised at varying dates, and that the publication year referenced here refers only to the date that the guideline set was accessed online.

Management of In-Transit Disease

Year: 2019
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for patients with melanoma who have developed in-transit metastases. The guideline discusses the treatment of in-transit disease, and provides recommendations on primary treatment, second-line treatment, adjuvant treatment, and radiation therapy. The primary outcomes of interest are progression-free survival and overall survival.

Melanoma

Year: 2019
AGREE II score: Unavailable
Developer organization: BC Cancer Agency
This is a clinical practice guideline for patients who have been diagnosed with melanoma, and those who are at high risk for melanoma. The guideline provides recommendations on prevention, screening of high risk individuals, diagnosis, staging, treatment, and follow-up. Treatment strategies explored include surgery, radiation therapy, and adjuvant chemotherapy, and recommendations are separated based on disease type. Please note that the sub-sections within this set were published and revised at varying dates, and that the publication year referenced here refers only to the date that the guideline set was accessed online.

Systemic Adjuvant Therapy for Adult Patients at High Risk for Recurrent Melanoma

Year: 2019
AGREE II score: Available
Developer organization: Cancer Care Ontario
This is a clinical practice guideline for adult patients with completely resected cutaneous or mucosal melanoma, who are at a high risk for recurrence. The guideline examines the use of adjuvant systemic therapy for the prevention of recurrence in these patients. Molecular testing is discussed, and different recommendations are made based on the presence or absence of BRAF V600E or V600K mutations.

Mohs Micrographic Surgery

Year: 2019
AGREE II score: Available
Developer organization: Alberta Health Services
This is a clinical practice guideline for the surgical management of nonmelanoma skin cancer (NMSC) in adult patients. This guideline specifically focuses on the indications for Mohs micrographic surgery (MMS) to treat basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). Clinical parameters such as location, size, borders, and site(s) of prior radiation therapy, as well as pathologic parameters such as growth pattern, degree of differentiation, and depth, are considered for risk-stratifying BCC and SCC patients.

Primary Cutaneous Lymphomas, Version 2.2019

Year: 2018
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
A clinical practice guideline on the diagnosis, workup, and treatment of patients who have been diagnosed with or are suspected of having primary cutaneous B-cell lymphomas (PCBCLs). The guideline focuses on the three main types of PCBCLs: primary cutaneous marginal zone lymphoma (PCMZL), primary cutaneous follicle-center lymphoma (PCFCL), and primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL, leg type). Recommendations for treatment are provided based on lymphoma type and whether treatment is for initial, relapsed, or refractory disease.

Penile Cancer, Version 2.2018

Year: 2018
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for the management of squamous cell carcinoma (SCC) of the penis. The guideline examines the diagnosis, treatment, and follow-up for patients with this form of cancer. Outcomes of interest include optimizing therapeutic efficacy and minimizing treatment-related morbidity.

An Update on the Society for Immunotherapy of Cancer Consensus Statement on Tumor Immunotherapy for the Treatment of Cutaneous Melanoma: Version 2.0

Year: 2018
AGREE II score: Available
Developer organization: Society for Immunotherapy of Cancer
This is a clinical practice guideline for patients with cutaneous melanoma. The guideline examines the immunotherapy options for the treatment of this patient population. Topics of interest include the different immunotherapy options for every stage of melanoma and special issues in tumour immunotherapy.

British Association of Dermatologists and British Photodermatology Group Guidelines for Topical Photodynamic Therapy 2018

Year: 2018
AGREE II score: Available
Developer organization: British Association of Dermatologists
This is a clinical practice guideline for patients with nonmelanoma skin cancer, precancerous lesions, or infectious and inflammatory dermatoses. The guideline examines the use of topical photodynamic therapy (PDT) in these patients. Photosensitizing agents, photodynamic diagnosis, light sources and dosimetry, protocols for delivery of photodynamic therapy, and adverse effects are also discussed.

Patient Indications for Mohs Micrographic Surgery

Year: 2018
AGREE II score: Available
Developer organization: Cancer Care Ontario
This clinical practice guideline provides recommendations on the use of Mohs micrographic surgery (MMS) for adult patients diagnosed with skin cancer. MMS is compared to other surgical excision techniques, as well as other treatment modalities such as radiation. Guidance is provided on the indications and considerations for appropriate use of MMS, including disease stage, aesthetic outcomes, patient comorbidities, and patient preferences. Outcomes of interest include cure rate, recurrence rate, quality of life, and adverse events.

Primary Cutaneous B-Cell Lymphomas, Version 2.2018

Year: 2018
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
A clinical practice guideline on the diagnosis, work-up, and treatment of patients who have been diagnosed with or are suspected of having primary cutaneous B-cell lymphomas (PCBCLs). The guideline focuses on the three main types of PCBCLs: primary cutaneous marginal zone lymphoma (PCMZL), primary cutaneous follicle-center lymphoma (PCFCL), and primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL, leg type). Recommendations for treatment are provided based on lymphoma type and whether treatment is for initial, relapsed, or refractory disease.

Behavioral Counseling to Prevent Skin Cancer: US Preventive Services Task Force Recommendation Statement

Year: 2018
AGREE II score: Available
Developer organization: United States Preventive Services Task Force
This is a clinical practice guideline for the prevention and screening of skin cancer. Behavioural counselling recommendations are provided for young adults, adolescents, children, and parents of young children. Outcomes of interest include changes in sun protection behaviours, frequency of sunburn, and frequency of skin cancer.

Merkel Cell Carcinoma, Version 1.2019

Year: 2018
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with Merkel cell carcinoma. The guideline provides recommendations on diagnosis, workup, staging, radiation therapy, chemotherapy, follow-up, and recurrence. Specific recommendations are provided for the postoperative management of primary tumours, management of the draining nodal basin, and treatment of distant metastatic disease.

British Association of Dermatologists and U.K. Cutaneous Lymphoma Group Guidelines for the Management of Primary Cutaneous Lymphomas 2018

Year: 2018
AGREE II score: Available
Developer organization: British Association of Dermatologists
This is a clinical practice guideline for the management of adult patients with primary cutaneous B-cell and T-cell lymphomas. This guideline does not include patients presenting with or found to have skin involvement as part of a systemic lymphoma. Treatment recommendations are organized by clinicopathological subtypes of lymphomas and are further stratified based on the stage of the disease. Economic and practical considerations of also discussed.

Guidelines of Care for the Management of Cutaneous Squamous Cell Carcinoma

Year: 2017
AGREE II score: Available
Developer organization: American Academy of Dermatology
This is a clinical practice guideline for patients with cutaneous squamous cell carcinoma (cSCC). The guideline provides recommendations for the evaluation and management of patients with cSCC. Topics of interest include biopsy techniques and histopathologic assessment, tumour staging, surgical and non-surgical management, follow-up and prevention of recurrence, and management of advanced disease.

Vulvar Cancer (Squamous Cell Carcinoma), Version 1.2018

Year: 2017
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for women with vulvar cancer, and particularly those with squamous cell carcinoma (SCC) of the vulva. The guideline examines diagnosis and workup, as well as primary treatment, adjuvant radiotherapy and chemotherapy, and surveillance of these pa